2021 fda drug approvals with blockbuster potential

2021 fda drug approvals with blockbuster potential2021 fda drug approvals with blockbuster potential2021 fda drug approvals with blockbuster potential2021 fda drug approvals with blockbuster potential2021 fda drug approvals with blockbuster potential

2021 FDA Drug Approvals With BLOCKBUSTER ($1+ Billion) Potential COVID-19 mRNA Vaccine: $36 Billion peak sales Vygart, efgartimod : $3 Billion peak sales Leqvio, inclisiran: $3 Billion peak sales * Products that won Emergency Use Authorizations for deployment in response to the pandemic such as the Moderna and Johnson & Johnson vaccines are not included Source: FiercePharma Swipe to Read More 2021 FDA Drug Approvals Comirnaty Active ingredient: COVID-19 Vaccine, mRNA Disease: COVID-19 Peak sales estimate: $36 billion Approved: Aug 23 Company: Pfizer Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Vyvgart Active ingredient: efgartigimod Disease: myasthenia gravis Peak sales estimate: $3 billion Approved: Dec 17 Company: argenx Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Tezpire Active ingredient: Tezepelumab-ekko Disease: severe asthma Peak sales estimate: $2.5 billion in 2030 Approved: Dec 17 Company: Amgen, AstraZeneca Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Cabenuva Active ingredient: Cabotegravir and rilpivirine Disease: HIV Peak sales estimate: £2 billion (cabotegravir) Approved: Jan 21 Companies: GlaxoSmithKline’s ViiV Healthcare and Johnson & Johnson’s Janssen Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Leqvio Active ingredient: inclisiran Use: lowering of low-density lipoprotein cholesterol (LDL-C) Peak sales estimate: More than $2 billion Approved: Dec 22 Company: Novartis Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Scemblix Active ingredient: asciminib Disease: chronic myeloid leukemia Peak sales estimate: over $2 billion Approved: Oct 29 Company: Novartis Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Breyanzi Active ingredient: Lisocabtagene maraleucel Disease: Relapsed or refractory large B-cell lymphoma Peak sales estimate: $1 billion to $3 billion Approved: Feb Company: Bristol Myers Squibb Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Verquvo Active ingredient: Vericiguat Disease: Chronic heart failure Peak sales estimate: €1 billion Approved: Jan 19 Companies: Bayer and Merck & Co Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Lupkynis Active ingredient: Voclosporin Disease: Lupus nephritis Peak sales estimate: $1 billion by 2026 Approved: Jan 22 Company: Aurinia Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Abecma Active ingredient: idecabtagene vicleucel Disease: Multiple myeloma Peak sales estimate: $1.19 billion in 2026 Approved: March 26 Company: Bristol Myers Squibb Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Zynlonta Active ingredient: Loncastuximab tesirine-lpyl Disease: Certain types of relapsed or refractory large B-cell lymphoma Sales estimate: $1 billion by 2026 Approved: April 23 Company: ADC Therapeutics Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Lumakras Active ingredient: Sotorasib Disease: Lung cancer Peak sales estimate: $1.3 billion by 2025 Approved: May 28 Company: Amgen Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Aduhelm Active ingredient: aducanumab-avwa Disease: Alzheimer’s Peak sales estimate: $9 billion Approved: June Company: Biogen Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Kerendia Active ingredient: finerenone Disease: Chronic kidney disease associated with Type diabetes Peak sales estimate: $1.1 billion by 2026 Approved: July Company: Bayer Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Skytrofa Active ingredient: lonapegsomatropin-tcgd Disease: short stature due to inadequate secretion of endogenous growth hormone Peak sales estimate: $1.4 billion by 2026 Approved: Aug 25 Company: Ascendis Pharma Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Tivdak Active ingredient: tisotumab vedotin Disease: cervical cancer Peak sales estimate: $1.3 billion Approved: Sept 20 Companies: Seagen and Genmab Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Tavneos Active ingredient: avacopan Disease: vasculitis Peak sales estimate: $1.3 billion by 2035 Approved: Oct Company: ChemoCentryx Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Voxzogo Active ingredient: Vosoritide Disease: Achondroplasia Peak sales estimate: $1 billion Approved: Nov 19 Company: BioMarin Swipe to Read More Source: FiercePharma 2021 FDA Drug Approvals Adbry Active ingredient: tralokinumab Disease: atopic dermatitis Peak sales estimate: $1.6 billion in 2027 Approved: Dec 28 Company: Leo Pharma Swipe to Read More Source: FiercePharma Source: FiercePharma